ArticlePediatric surgery international2026
CD200 expression predicts poor prognosis in neuroblastoma: a potential biomarker for treatment stratification-a retrospective cohort study.
Article in Pediatric surgery international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeHigh-risk neuroblastomas carry a poor prognosis, and the role of the immunosuppressive glycoprotein CD200 in this disease remains unclear. In this study, we investigated the role of CD200 expression.
methodsWe retrospectively analyzed CD200 expression in 45 neuroblastoma specimens using immunohistochemistry (IHC). Its association with clinicopathological features, patient survival, and tumor-infiltrating lymphocytes (TILs) density was evaluated. Changes in CD200 expression during chemotherapy were examined in the high-risk subgroup. The functional role of CD200 in chemosensitivity was assessed in vitro using siRNA-mediated silencing in SH-SY5Y and IMR-32 neuroblastoma cell lines.
resultsHigh CD200 expression was significantly associated with advanced-stage disease, recurrence, and poor overall survival (5-year OS: 57.3% vs. 100% in low-CD200, p = 0.007). High-CD200 tumors showed significantly reduced infiltration of CD4 + and CD8 + T cells. In high-risk patients, persistently high or increased post-chemotherapy CD200 expression was correlated with 100% recurrence and mortality. In vitro, CD200 silencing significantly enhanced the cytotoxic effects of cisplatin.
conclusionCD200 is a strong negative prognostic biomarker in neuroblastoma, associated with an immunosuppressive tumor microenvironment and chemoresistance. It represents a promising candidate for treatment stratification and a potential therapeutic target for improving outcomes in high-risk patients.
Indexed as
Identifiers
41569456What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.